Boston Scientific expands heart device portfolio with $14.5 billion Penumbra deal

Boston Scientific will buy medtech firm Penumbra for about $14.5 billion to expand its cardiovascular device offerings, and the companies expect the transaction to be completed in 2026.

Boston Scientific said it will buy medtech firm Penumbra in a deal valued at about $14.5 billion. The companies say the acquisition is intended to broaden Boston Scientific's cardiovascular device portfolio. The transaction is the largest acquisition by the Massachusetts-based company in two decades. Boston Scientific said Penumbra's products will contribute to revenue and margin improvement over time. Key details: - The deal is valued at about $14.5 billion and is aimed at expanding Boston Scientific's cardiovascular offerings. - Penumbra is expected to generate about $1.4 billion in sales in 2025, according to the article. - The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close, and shareholders can elect $374 in cash or 3.8721 Boston Scientific shares; the payment mix is about 73% cash and 27% stock. - The article says Penumbra's shares rose over 13% to $354.70 in premarket trading after the announcement. - The transaction is expected to be completed in 2026, and Penumbra's chairman and CEO Adam Elsesser will join Boston Scientific's board upon close. Summary: The acquisition gives Boston Scientific access to Penumbra's devices for conditions including pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms. The companies expect to complete the transaction in 2026 and to integrate Penumbra's product lines into Boston Scientific's cardiovascular business.